Biography
Stephen Lin is a senior science officer at California’s stem cell agency, CIRM. He joined the Agency in 2015 to oversee the its $32M initiative to create a repository of iPSCs from over 2800 individuals covering both genetically complex and rare diseases, as well as a $40M genomics initiative that applies cutting edge genomics and bioinformatics approaches to stem cell research and therapeutic development. He is also program lead on a $15M award to create a preclinical research organization termed the Translating Center that focuses on preparing stem cell therapy candidates for clinical trials through support with process development, safety/toxicity studies, and manufacturing. From 2012 he had been a staff scientist and team lead at Thermo Fisher Scientific (formerly Life Technologies). Prior to that he was a scientist since 2006 at StemCells, Inc of California in the area of liver cell therapeutics. Dr. Lin received his Ph.D. from Washington University in St. Louis in 2002 under Jeffrey Gordon and did his postdoctoral research at Harvard University under Stanley Korsmeyer.
Research Interest
Stem Cell related therapies, Therapeutic Development, Transplantation, Regenerative Medicine
Biography
Chris joined Immunocore as Chief Medical Officer in April 2015. She has extensive experience in oncology drug development, with expertise in both clinical development and translational medicine. Prior to joining Immunocore Chris led two early development programmes at Novartis in checkpoint inhibition and PI3 kinase inhibition. She has also served as International Project Team Leader at Morphotek Inc., the monoclonal antibody company acquired by Eisai Co. Ltd in 2007, where she led the early clinical development team responsible for monoclonal antibody development against novel targets. Chris graduated with an M.D. and Ph.D from the University of Pennsylvania, where she studied patient responses to tumour antigens with Dr Robert Vonderheide in the division of Translational Research under the direction of Dr Carl June.
Research Interest
Oncology Drug Development, Clinical development and Translational Medicine
Biography
Raj Kumar, PhD is Director of Research and a Professor of Biochemistry in the Basic Sciences Department. He received his PhD and did his Postdoctoral work at the University of Texas Medical Branch at Galveston. His research focuses on: Biochemistry, Cell Biology, Molecular Biology; Protein Biochemistry, Structural Biology, and Biophysical Chemistry; Thermodynamics of protein Folding/Unfolding; Cancer Biology; Pharmacology and pathology of Gastrointestinal Tract; Diabetes; Signal Transduction, Post transcriptional Modifications; Endocrinology; Biology of Nuclear Hormone Receptors; Inflammation; and, Allergy and Asthma. Raj comes to us from the University of Texas Medical Branch.
Research Interest
Structure:function studies of the steroid hormone receptors